This novel platform technology has been developed to fulfil a growing need in the market for a portable in-field and rapid multiplex detection QPCR system. This system requirement comes from a number of our key stakeholders some of which include healthcare professionals for rapid response to outbreaks of pandemic diseases and in the agricultural sector for surveillance of notifiable animal diseases. Diseases such as Lassa, Ebola, Marburg, Rift Valley Fever and Crimean Congo Haemorrhagic Fever are highly contagious with an extremely high mortality rate. Therefore, infected patients must be tested, diagnosed, quarantined and treated as quickly as possible in order to help save their lives and contain the spread of infection.
The QuRapID-LV™ has been designed with usability, speed of detection and sensitivity in mind. What makes the system so unique and innovative is its ability to directly amplify a range of RNA or DNA targets from crude samples in-field in under 60 minutes via a closed tube real-time one step reaction without the need for a separate lab based nucleic acid extraction process. This is made possible by the patented underlying technology that we have carefully engineered to ensure optimal performance, reliability, repeatability and gold standard results. Our aim is to use this novel molecular technology to improve global health outcomes and most importantly save lives.